Charles Schwab’s CorMedix CRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.85M | Buy |
618,172
+15,206
| +3% | +$120K | ﹤0.01% | 2495 |
|
|
2026
Q1 | $4.09M | Sell |
602,966
-7,962
| -1% | -$58.9K | ﹤0.01% | 2486 |
|
|
2025
Q4 | $7.11M | Buy |
610,928
+26,446
| +5% | +$292K | ﹤0.01% | 2294 |
|
|
2025
Q3 | $6.8M | Buy |
584,482
+389,027
| +199% | +$4.7M | ﹤0.01% | 2293 |
|
|
2025
Q2 | $2.41M | Buy |
195,455
+18,267
| +10% | +$202K | ﹤0.01% | 2610 |
|
|
2025
Q1 | $1.09M | Buy |
177,188
+2,770
| +2% | +$28.7K | ﹤0.01% | 2808 |
|
|
2024
Q4 | $1.41M | Buy |
174,418
+17,869
| +11% | +$178K | ﹤0.01% | 2791 |
|
|
2024
Q3 | $1.26M | Hold |
156,549
| – | – | ﹤0.01% | 2850 |
|
|
2024
Q2 | $678K | Buy |
156,549
+12,132
| +8% | +$61.6K | ﹤0.01% | 3067 |
|
|
2024
Q1 | $612K | Sell |
144,417
-6,877
| -5% | -$23.8K | ﹤0.01% | 2953 |
|
|
2023
Q4 | $569K | Buy |
151,294
+8,040
| +6% | +$27.7K | ﹤0.01% | 3029 |
|
|
2023
Q3 | $530K | Buy |
143,254
+18,651
| +15% | +$74.2K | ﹤0.01% | 3018 |
|
|
2023
Q2 | $494K | Buy |
124,603
+101,999
| +451% | +$505K | ﹤0.01% | 3058 |
|
|
2023
Q1 | $93.6K | Buy |
22,604
+8,656
| +62% | +$35.4K | ﹤0.01% | 3260 |
|
|
2022
Q4 | $58.9K | Hold |
13,948
| – | – | ﹤0.01% | 3329 |
|
|
2022
Q3 | $40K | Hold |
13,948
| – | – | ﹤0.01% | 3381 |
|
|
2022
Q2 | $57K | Sell |
13,948
-84,742
| -86% | -$315K | ﹤0.01% | 3376 |
|
|
2022
Q1 | $541K | Buy |
98,690
+4,401
| +5% | +$20.2K | ﹤0.01% | 3076 |
|
|
2021
Q4 | $430K | Hold |
94,289
| – | – | ﹤0.01% | 3191 |
|
|
2021
Q3 | $439K | Hold |
94,289
| – | – | ﹤0.01% | 3181 |
|
|
2021
Q2 | $647K | Buy |
94,289
+11,711
| +14% | +$93.2K | ﹤0.01% | 3082 |
|
|
2021
Q1 | $825K | Buy |
82,578
+1,997
| +2% | +$21K | ﹤0.01% | 2913 |
|
|
2020
Q4 | $599K | Buy |
80,581
+10,823
| +16% | +$73.6K | ﹤0.01% | 2922 |
|
|
2020
Q3 | $421K | Buy |
69,758
+6,806
| +11% | +$34.2K | ﹤0.01% | 2923 |
|
|
2020
Q2 | $397K | Buy |
62,952
+3,060
| +5% | +$14.2K | ﹤0.01% | 2920 |
|
|
2020
Q1 | $216K | Hold |
59,892
| – | – | ﹤0.01% | 2993 |
|
|
2019
Q4 | $437K | Buy |
59,892
+4,911
| +9% | +$30K | ﹤0.01% | 2871 |
|
|
2019
Q3 | $351K | Hold |
54,981
| – | – | ﹤0.01% | 2930 |
|
|
2019
Q2 | $494K | Buy |
+54,981
| New | +$431K | ﹤0.01% | 2816 |
|
|
2019
Q1 | – | Sell |
-5,920
| Closed | -$39K | – | 3193 |
|
|
2018
Q4 | $39K | Buy |
+5,920
| New | +$39.6K | ﹤0.01% | 3135 |
|
|
2016
Q2 | – | Sell |
-9,075
| Closed | -$121K | – | 3115 |
|
|
2016
Q1 | $121K | Hold |
9,075
| – | – | ﹤0.01% | 2969 |
|
|
2015
Q4 | $93K | Hold |
9,075
| – | – | ﹤0.01% | 3045 |
|
|
2015
Q3 | $91K | Hold |
9,075
| – | – | ﹤0.01% | 3043 |
|
|
2015
Q2 | $177K | Buy |
+9,075
| New | +$311K | ﹤0.01% | 2997 |
|
Other funds holding CRMD
DTC
RA
OAM
Charles Schwab's CRMD Position: Q2 2026 in Review
Charles Schwab increased its CorMedix (CRMD) stake by 2.5% in Q2 2026, buying an estimated $120K and bringing the position to 618,172 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2495.
Charles Schwab first reported a position in CRMD in Q2 2015 and has held it in 34 quarters since. The position peaked at $7.11M in Q4 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.
- Charles Schwab held 618,172 shares of CorMedix worth $4.85M as of Q2 2026.
- Charles Schwab bought 15,206 CorMedix shares in Q2 2026, an estimated $120K.
- CorMedix made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2495 holding.
- Charles Schwab first reported a position in CorMedix in Q2 2015 and has held it in 34 quarters since.
- Charles Schwab's CorMedix position peaked at $7.11M in Q4 2025.
- 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.